In the BST-CarGel study, VirtualScopics is providing blinded data analysis of quantitative magnetic resonance imaging which will allow BioSyntech to demonstrate BST-CarGel’s potential for affecting the quantity and quality of the repaired cartilage as their primary endpoint.
Jeff Markin, president and CEO of VirtualScopics, said: “We are very pleased to be working with BioSyntech on this unique Canadian-European pivotal trial. The quantitative nature of these endpoints offers the opportunity to design cartilage repair trials that may be smaller or shorter in comparison to conventional designs which use more qualitative or subjective endpoints. We look forward to providing BioSyntech the critical information they need to demonstrate the effectiveness of their product.”